Published in Healthcare Finance, Tax and Law Weekly, November 2nd, 2005
The long-term, 828-patient, randomized, double-blind, placebo-controlled study evaluating safety and efficacy of Lunesta also included a 2-week discontinuation phase in which all patients were administered placebo. This study is the second long-term, 6-month, double-blind, placebo-controlled study of Lunesta in patients suffering from chronic insomnia. The results of this study augment the findings of the first 6-month study, which was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.